Degu Amsalu, Terefe Ermias Mergia, Some Eliab Seroney, Tegegne Gobezie T
Department of Pharmaceutics and Pharmacy Practice, School of Pharmacy and Health Sciences, United States International University-Africa, Nairobi, Kenya.
Department of Pharmacology and Clinical Pharmacy, School of Pharmacy, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
Cancer Manag Res. 2022 Apr 22;14:1525-1540. doi: 10.2147/CMAR.S361485. eCollection 2022.
The treatment outcome of cancer is poor in the African setting due to inadequate treatment and diagnostic facilities. However, there is a paucity of data on solid cancers in Kenya. Hence, this study aimed to investigate the treatment outcomes and its determinant factors among adult patients diagnosed with selected solid malignancies at Kenyatta National Hospital (KNH).
A prospective cohort study was employed at the Oncology Department of KNH from 1 July 2020 to 31 December 2021. All new patients with a confirmed diagnosis of lymphoma, prostate cancer and breast cancer were studied. A consecutive sample of 99 breast cancer, 50 lymphomas, and 82 prostate cancer patients was included in the study. Semi-structured questionnaires consisting of socio-demographics, clinical characteristics, and quality of life were employed to collect the data. All enrolled patients were followed prospectively for 12 months. Treatment outcomes were reported as mortality, cancer-specific survival and health-related quality of life. The data were entered and analyzed using the SPSS 20.0 statistical software. Survival outcomes and its predictors were evaluated using the Kaplan-Meier analysis and Cox regression analyses, respectively.
The study showed that the mortality rate among breast and prostate cancer patients was 3% and 4.9%, respectively. In contrast, the mortality rate was 10% among lymphoma patients. Most of the patients had partial remission and a good overall global health-related quality of life. Older age above 60 years, co-morbidity, distant metastasis and advanced stages of disease were significant predictors of mortality.
Although the mortality was not high at 12 months, only a few patients had complete remission. For many patients, the disease was progressing, despite 12-month mortality was not high. Therefore, longer follow-up will be required to report cancer mortality accurately. In addition, most of the patients had a good overall global health-related quality of life.
由于治疗和诊断设施不足，非洲地区癌症的治疗效果较差。然而，肯尼亚关于实体癌的数据匮乏。因此，本研究旨在调查在肯雅塔国家医院（KNH）被诊断为选定实体恶性肿瘤的成年患者的治疗效果及其决定因素。
2020年7月1日至2021年12月31日在KNH肿瘤科开展了一项前瞻性队列研究。对所有确诊为淋巴瘤、前列腺癌和乳腺癌的新患者进行研究。该研究纳入了99例乳腺癌、50例淋巴瘤和82例前列腺癌患者的连续样本。采用由社会人口统计学、临床特征和生活质量组成的半结构化问卷收集数据。所有入组患者前瞻性随访12个月。治疗结果报告为死亡率、癌症特异性生存率和健康相关生活质量。使用SPSS 20.0统计软件录入和分析数据。分别采用Kaplan-Meier分析和Cox回归分析评估生存结果及其预测因素。
研究表明，乳腺癌和前列腺癌患者的死亡率分别为3%和4.9%。相比之下，淋巴瘤患者的死亡率为10%。大多数患者有部分缓解，总体健康相关生活质量良好。60岁以上的高龄、合并症、远处转移和疾病晚期是死亡率的重要预测因素。
尽管12个月时死亡率不高，但只有少数患者完全缓解。对于许多患者来说，尽管12个月死亡率不高，但疾病仍在进展。因此，需要更长时间的随访才能准确报告癌症死亡率。此外，大多数患者总体健康相关生活质量良好。
